Measurement of CYP1A2 activity: A focus on caffeine as a probe

Current Drug Metabolism

Volumn 13, Issue 5, 2012, Pages 667-678

  Perera, Vidya ^a,b   Gross, Annette S ^a,c   McLachlan, Andrew J ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Department of Microbiology and Infectious Diseases   (Australia)

^c GLAXOSMITHKLINE   (Australia)

Author keywords

CYP1A2; Drug metabolism; Phenotyping; Plasma; Probe; Saliva

Indexed keywords

CAFFEINE; CARBON DIOXIDE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; METHYLXANTHINE; PARAXANTHINE; THEOBROMINE; THEOPHYLLINE;

AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BREATH ANALYSIS; CAFFEINE BREATH TEST; DEMETHYLATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG PH; DRUG PROTEIN BINDING; DRUG URINE LEVEL; DRUG WITHDRAWAL; ENZYME ACTIVITY; EXPIRED AIR; FERMENTATION; GENETIC POLYMORPHISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIPID SOLUBILITY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; PHARMACOLOGICAL PARAMETERS; PHENOTYPE; PROTEIN FUNCTION; SALIVA ANALYSIS; SENSITIVITY AND SPECIFICITY; URINALYSIS; URINE FLOW RATE; URINE PH;

EID: 84861892530     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200211209050667     Document Type: Article

References (152)

1. Altayli, E.; Gunes, S.; Yilmaz, A.F.; Goktas, S.; Bek, Y. CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population. Int. Urol. Nephrol., 2009, 41(2), 259-66.
2. B'Chir, F.; Pavanello, S.; Knani, J.; Boughattas, S.; Arnaud, M.J.; Saguem, S. CYP1A2 genetic polymorphisms and adenocarcinoma lung cancer risk in the Tunisian population. Life Sci., 2009, 84(21-22), 779-84.
3. Hong, C.-C.; Tang, B.-K.; Hammond, G.L.; Tritchler, D.; Yaffe, M.; Boyd, N.F. Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res., 2004, 6(4), 352-65.
4. Vistisen, K.; Loft, S.; Olsen, J.H.; Vallentin, S.; Ottesen, S.; Hirsch, F.R.; Poulsen, H.E. Low CYP1A2 activity associated with testicular cancer. Carcinogenesis, 2004, 25(6), 923-9.
5. Eaton, D.L.; Gallagher, E.P.; Bammler, T.K.; Kunze, K.L. Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics, 1995, 5(5), 259-74.
6. Bertilsson, L.; Carrillo, J.A.; Dahl, M.L.; Llerena, A.; Alm, C.; Bondesson, U.; Lindstrom, L.; Rodriguez de la Rubia, I.; Ramos, S.; Benitez, J. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br. J. Clin. Pharmacol., 1994, 38(5), 471-3.
7. Brosen, K.; Skjelbo, E.; Rasmussen, B.B.; Poulsen, H.E.; Loft, S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol., 1993, 45, 1211-1214.
8. Mahner, M.; Kary, M. What exactly are genomes, genotypes and phenotypes? And what about phenomes? J. Theor. Biol., 1997, 186(1), 55-63.
9. Kalow, W.; Tang, B.K. The use of caffeine for enzyme assays: a critical appraisal. Clin. Pharmacol. Ther., 1993, 53(5), 503-14.
10. Frye, R.F. Probing the world of cytochrome P450 enzymes. Mol. Interven., 2004, 4(3), 157-62.
11. Tassaneeyakul, W.; Birkett, D.J.; Veronese, M.E.; McManus, M.E.; Tukey, R.H.; Quattrochi, L.C.; Gelboin, H.V.; Miners, J.O. Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J. Pharmacol. Exp. Ther., 1993, 265(1), 401-7.
12. Tucker, G.T.; Rostami-Hodjegan, A.; Jackson, P.R. Determination of drug-metabolizing enzyme activity in vivo: pharmacokinetic and statistical issues. Xenobiotica, 1998, 28(12), 1255-73.
13. Miners, J.O.; Birkett, D.J. The use of caffeine as a metabolic probe for human drug metabolizing enzymes. Gen. Pharmacol., 1996. 27(2): p. 245-9.
14. Hartter, S.; Ursing, C.; Morita, S.; Tybring, G.; von Bahr, C.; Christensen, M.; Rojdmark, S.; Bertilsson, L. Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study. Clin. Pharmacol. Ther., 2001, 70(1), 10-6.
15. Bartoli, A.; Xiaodong, S.; Gatti, G.; Cipolla, G.; Marchiselli, R.; Perucca, E. The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: a comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate. Ther. Drug Monit., 1996, 18(5), 586-91.
16. Rasmussen, B.B.; Brosen, K. Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans. Br. J. Clin. Pharmacol., 1997, 43(3), 253-8.
17. Larsen, J.; Hansen, L.; Brosen, K. Tacrine is not an ideal probe drug for meauring CYP1A2 activity in vivo. Br. J. Clin. Pharmacol., 1999, 48(5), 663-8.
18. Backman, J.T.; Schroder, M.T.; Neuvonen, P.J. Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine. Eur. J. Clin. Pharmacol., 2008, 64, 17-24.
19. Arnaud, M.J. The pharmacology of caffeine. Prog. Drug. Res., 1987, 31 273-313.
20. Benowitz, N.L. Clinical pharmacology of caffeine. Annu. Rev. Med., 1990, 41, 277-88.
21. Notarianni, L.J.; Oliver, S.E.; Dobrocky, P.; Bennett, P.N.; Silverman, B.W. Caffeine as a metabolic probe: a comparison of the metabolic ratios used to assess CYP1A2 activity. Br. J. Clin. Pharmacol., 1995, 39(1), 65-9.
22. Fuhr, U.; Rost, K.L. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics, 1994, 4(3), 109-16.
23. Gilbert, R.M. Caffeine consumption. Prog. Clin. Biol. Res., 1984, 158, 185-213.
24. Bunker, M.L.; McWilliams, M. Caffeine content of common beverages. J. Am. Diet Assoc., 1979, 74(1), 28-32.
25. Lelo, A.; Miners, J.O.; Robson, R.; Birkett, D.J. Assessment of caffeine exposure: caffeine content of beverages, caffeine intake, and plasma concentrations of methylxanthines. Clin. Pharmacol. Ther, 1986, 39(1), 54-9.
26. Barone, J.J.; Roberts, H.R. Caffeine consumption. Food Chem. Toxicol., 1996, 34(1), 119-29.
27. Viani, R. Caffeine consumption. in Thai FDA and ILSI, Proceedings of the Caffeine Workshop, 1996, Bangkok.
28. World Resource Institute. Countries by coffee consumption per capita. http://earthtrends.wri.org/searchable-db/index.php theme=8&variable-ID= 1677&action=select-countries.(Accessed July 22, 2011)
29. Carrillo, J.A.; Christensen, M.; Ramos, S.I.; Alm, C.; Dahl, M.L.; Benitez, J.; Bertilsson, L. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. Ther. Drug Monit., 2000, 22(4), 409-17.
30. Perera, V.; McLachlan, A.J.; Gross, A.S. Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma. Biomed. Chromatogr., 2010, 24(10), 1136-44.
31. Blanchard, J.; Sawers, S.J. The absolute bioavailability of caffeine in man. Eur. J. Clin. Pharmacol., 1983, 24(1), 93-8.
32. Bonati, M.; Latini, R.; Galletti, F.; Young, J.F.; Tognoni, G.; Garattini, S. Caffeine disposition after oral doses. Clin. Pharmacol. Ther., 1982, 32(1), 98-106.
33. Cheng, W.S.; Murphy, T.L.; Smith, M.T.; Cooksley, W.G.; Halliday, J.W.; Powell, L.W. Dose-dependent pharmacokinetics of caffeine in humans: relevance as a test of quantitative liver function. Clin. Pharmacol. Ther., 1990, 47(4), 516-24.
34. Renner, E.; Wietholtz, H.; Huguenin, P.; Arnaud, M.J.; Preisig, R. Caffeine: a model compound for measuring liver function. Hepatology, 1984, 4(1), 38-46.
35. Perera, V.; Gross, A.S.; McLachlan, A.J. Pharmacokinetics of caffeine in plasma and saliva and the influence of caffeine abstinence on CYP1A2 metrics. J. Pharm. Pharmacol., 2011, 63(9), 1161-1168.
36. Burg, A.W. Physiological disposition of caffeine. Drug Metab. Rev., 1975, 4(2), 199-228.
37. Denaro, C.P.; Brown, C.R.; Wilson, M.; Jacob, P., 3rd; Benowitz, N.L. Dose-dependency of caffeine metabolism with repeated dosing. Clin. Pharmacol. Ther., 1990, 48(3), 277-85.
38. Spigset, O.; Hagg, S.; Soderstrom, E.; Dahlqvist, R. Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance. Eur. J. Clin. Pharmacol., 1999, 54(12), 943-6.
39. Tang-Liu, D.D.; Williams, R.L.; Riegelman, S. Disposition of caffeine and its metabolites in man. J. Pharmacol. Exp. Ther., 1983, 224(1), 180-5.
40. Zylber-Katz, E.; Granit, L.; Levy, M. Relationship between caffeine concentrations in plasma and saliva. Clin. Pharmacol. Ther., 1984, 36(1), 133-7.
41. Blanchard, J. Protein binding of caffeine in young and elderly males. J. Pharm. Sci., 1982, 71(12), 1415-8.
42. Somani, S.M.; Gupta, P. Caffeine: a new look at an age-old drug. Int. J. Clin. Pharmacol. Ther. Toxicol., 1988, 26(11), 521-33.
43. Grant, D.M.; Tang, B.K.; Kalow, W. Variability in caffeine metabolism. Clin. Pharmacol. Ther., 1983, 33(5), 591-602.
44. Arnaud, M.J.; Thelin-Doerner, A.; Ravussin, E.; Acheson, K.J. Study of the demethylation of [1,3,7-Me-13C] caffeine in man using respiratory exchange measurements. Biomed. Mass Spectrom, 1980, 7(11-12), 521-4.
45. Butler, M.A.; Iwasaki, M.; Guengerich, F.P.; Kadlubar, F.F. Human cytochrome P-450PA (P-450IA2), the phenacetin Odeethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86(20), 7696-700.
46. Campbell, M.E.; Grant, D.M.; Inaba, T.; Kalow, W. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab. Dispos., 1987, 15(2), 237-49.
47. Gu, L.; Gonzalez, F.J.; Kalow, W.; Tang, B.K. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNAexpressed human CYP1A2 and CYP2E1. Pharmacogenetics, 1992, 2(2), 73-7.
48. Gu, L., Caffeine metabolism as index of cytochrome P4501A2 activity, in Medicine 1992, University of Toronto: Toronto. p. 116.
49. Ha, H.R.; Chen, J.; Krahenbuhl, S.; Follath, F. Biotransformation of caffeine by cDNA-expressed human cytochromes P-450. Eur. J. Clin. Pharmacol., 1996, 49(4), 309-15.
50. Berthou, F.; Flinois, J.P.; Ratanasavanh, D.; Beaune, P.; Riche, C.; Guillouzo, A. Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes. Drug Metab. Dispos., 1991, 19(3), 561-567.
51. Tassaneeyakul, W.; Birkett, D.J.; McManus, M.E.; Veronese, M.E.; Andersson, T.; Tukey, R.H.; Miners, J.O. Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochem. Pharmacol., 1994, 47(10), 1767-76.
52. Lambert, G.H.; Kotake, A.N.; Schoeller, D. The CO2 breath tests as monitors of the cytochrome P450 dependent mixed function monooxygenase system. Prog. Clin. Biol. Res., 1983, 135, 119-45.
53. Lelo, A.; Birkett, D.J.; Robson, R.A.; Miners, J.O. Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. Br. J. Clin. Pharmacol., 1986, 22(2), 177-82.
54. Fuhr, U.; Doehmer, J.; Battula, N.; Wolfel, C.; Kudla, C.; Keita, Y.; Staib, A.H. Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochem. Pharmacol., 1992, 43(2), 225-35.
55. Eugster, H.P.; Probst, M.; Wurgler, F.E.; Sengstag, C. Caffeine, estradiol, and progesterone interact with human CYP1A1 and CYP1A2. Evidence from cDNA-directed expression in Saccharomyces cerevisiae. Drug Metab. Dispos., 1993, 21(1), 43-49.
56. Schweikl, H.; Taylor, J.A.; Kitareewan, S.; Linko, P.; Nagorney, D.; Goldstein, J.A. Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics, 1993, 3(5), 239-49.
57. Lelo, A.; Miners, J.O.; Robson, R.A.; Birkett, D.J. Quantitative assessment of caffeine partial clearances in man. Br. J. Clin. Pharmacol., 1986, 22(2), 183-6.
58. Fuhr, U.; Rost, K.L.; Engelhardt, R.; Sachs, M.; Liermann, D.; Belloc, C.; Beaune, P.; Janezic, S.; Grant, D.; Meyer, U.A.; Staib, A.H. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics, 1996, 6(2), 159-76.
59. Birkett, D.J.; Dahlqvist, R.; Miners, J.O.; Lelo, A.; Billing, B. Comparison of theophylline and theobromine metabolism in man. Drug Metab. Dispos., 1985, 13(6), 725-8.
60. Miners, J.O.; Attwood, J.; Birkett, D.J. Theobromine metabolism in man. Drug Metab. Dispos., 1982, 10(6), 672-5.
61. St-Pierre, M.V.; Spino, M.; Isles, A.F.; Tesoro, A.; MacLeod, S.M. Temporal variation in the disposition of theophylline and its metabolites. Clin. Pharmacol. Ther., 1985, 38(1), 89-95.
62. Sarkar, M.A.; Hunt, C.; Guzelian, P.S.; Karnes, H.T. Characterization of human liver cytochromes P-450 involved in theophylline metabolism. Drug Metab. Dispos., 1992, 20(1), 31-7.
63. Grygiel, J.J.; Wing, L.M.; Farkas, J.; Birkett, D.J. Effects of allopurinol on theophylline metabolism and clearance. Clin. Pharmacol. Ther., 26(5), 660-7.
64. Kalow, W.; Tang, B.K. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther, 1991. 50(5 Pt 1), 508-19.
65. Tanaka, E.; Ishikawa, A.; Yamamoto, Y.; Osada, A.; Tsuji, K.; Fukao, K.; Misawa, S.; Iwasaki, Y. A simple useful method for the determination of hepatic function in patients with liver cirrhosis using caffeine and its three major dimethylmetabolites. Int. J. Clin. Pharm. Ther., 1992, 30(9), 336-41.
66. Wittayalertpanya, S.; Israsena, S.; Thamaree, S.; Tongnopnoua, P.; Komolmit, P. Caffeine clearance by two point analysis: a measure of liver function in chronic liver disease. Tokai J. Exp. Clin. Med., 1996, 21(4-6), 195-201.
67. Alkaysi, H.N.; Salem, M.S.; el-Sayed, Y.M. High performance liquid chromatographic analysis of caffeine concentrations in plasma and saliva. J. Clin. Pharm. Ther., 1988, 13(2), 109-15.
68. Spigset, O.; Hagg, S.; Soderstrom, E.; Dahlqvist, R. The paraxanthine:caffeine ratio in serum or in saliva as a measure of CYP1A2 activity: when should the sample be obtained? Pharmacogenetics, 1999, 9(3), 409-12.
69. Kukongviriyapan, V.; Senggunprai, L.; Prawan, A.; Gaysornsiri, D.; Kukongviriyapan, U.; Aiemsa-Ard, J. Salivary caffeine metabolic ratio in alcohol-dependent subjects. Eur. J. Clin. Pharmacol., 2004, 60(2), 103-7.
70. Biederbick, W.; Joseph, G.; Rump, A.; Theisohn, M.; Klaus, W. Caffeine in saliva after peroral intake: early sample collection as a possible source of error. Ther. Drug Monit., 1997, 19(5), 521-4.
71. Woolridge, H.; Williams, J.; Cronin, A.; Evans, N.; Steventon, G.B. CYP1A2 in a smoking and a non-smoking population; correlation of urinary and salivary phenotypic ratios. Drug Metabol. Drug Interact., 2004, 20(4), 247-61.
72. Ghotbi, R.; Christensen, M.; Roh, H.-K.; Ingelman-Sundberg, M.; Aklillu, E.; Bertilsson, L. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur. J. Clin. Pharmacol., 2007, 63(6), 537-46.
73. Djordjevic, N.; Ghotbi, R.; Bertilsson, L.; Jankovic, S.; Aklillu, E. Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. Eur. J. Clin. Pharmacol., 2008, 64, 381-385.
74. Tang, B.K.; Zhou, Y.; Kadar, D.; Kalow, W. Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. Pharmacogenetics, 1994, 4(3), 117-24.
75. Catteau, A.; Bechtel, Y.C.; Poisson, N.; Bechtel, P.R.; Bonaiti- Pellie, C. A population and family study of CYP1A2 using caffeine urinary metabolites. Eur. J. Clin. Pharmacol., 1995, 47(5), 423-30.
76. Rasmussen, B.B.; Brix, T.H.; Kyvik, K.O.; Brosen, K. The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics, 2002, 12(6), 473-8.
77. Vistisen, K.; Poulsen, H.E.; Loft, S. Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. Carcinogenesis, 1992, 13(9), 1561-8.
78. Nakajima, M.; Yokoi, T.; Mizutani, M.; Shin, S.; Kadlubar, F.F.; Kamataki, T. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidem. Biomar., 1994, 3(5), 413-21.
79. Schrenk, D.; Brockmeier, D.; Morike, K.; Bock, K.W.; Eichelbaum, M. A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers. Eur. J. Clin. Pharmacol., 1997, 53(5), 361-367.
80. Butler, M.A.; Lang, N.P.; Young, J.F.; Caporaso, N.E.; Vineis, P.; Hayes, R.B.; Teitel, C.H.; Massengill, J.P.; Lawsen, M.F.; Kadlubar, F.F. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics, 1992, 2(3), 116-27.
81. Sinues, B.; Fanlo, A.; Bernal, M.L.; Mayayo, E.; Soriano, M.A.; Martinez-Ballarin, E. Influence of the urine flow rate on some caffeine metabolite ratios used to assess CYP1A2 activity. Ther. Drug Monit., 2002, 24(6), 715-21.
82. Aarons, L. Kinetics of drug - drug interactions. J. Pharmacokinet. Phar., 1981, 9(2), 181-190.
83. Mannhold, R., Molecuar drug properties: measurement and prediction. Molecular drug properties. Vol. 37. 2007, Dusseldorf: Wiley.
84. Hacker, M.P.; Messer, W.S.; Bachman, K.A., Pharmacology: Principles and Practice. Pharmacology: Principles and Practice, ed. A. Press. Vol. 1. 2009, London: Elsevier.
85. Lesko, L.J. Dose-dependent elimination kinetics of theophylline. Clin. Pharmacol. Ther., 1979, 14, 449-459.
86. Birkett, D.J.; Miners, J.O. Caffeine renal clearance and urine caffeine concentrations during steady state dosing. Implications for monitoring caffeine intake during sports events. Br. J. Clin. Pharmacol., 1991, 31(4), 405-8.
87. Campbell, M.E.; Spielberg, S.P.; Kalow, W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin. Pharmacol. Ther., 1987, 42(2), 157-65.
88. Denaro, C.P.; Wilson, M.; Jacob, P., 3rd; Benowitz, N.L. Validation of urine caffeine metabolite ratios with use of stable isotope-labeled caffeine clearance. Clin. Pharmacol. Ther., 1996, 59(3), 284-96.
89. Rostami-Hodjegan, A.; Nurminen, S.; Jackson, P.R.; Tucker, G.T. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics, 1996, 6(2), 121-49.
90. Sinues, B.; Saenz, M.A.; Lanuza, J.; Bernal, M.L.; Fanlo, A.; Juste, J.L.; Mayayo, E. Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow. Cancer Epidem. Biomar., 1999, 8(2), 159-66.
91. Landi, M.T.; Zocchetti, C.; Bernucci, I.; Kadlubar, F.F.; Tannenbaum, S.; Skipper, P.; Bartsch, H.; Malaveille, C.; Shields, P.; Caporaso, N.E.; Vineis, P. Cytochrome P4501A2: enzyme induction and genetic control in determining 4-aminobiphenylhemoglobin adduct levels. Cancer Epidem. Biomar., 1996, 5(9), 693-8.
92. Rost, K.L.; Roots, I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. Clin. Pharmacol. Ther., 1994, 55(4), 402-11.
93. Rost, K.L.; Brosicke, H.; Brockmoller, J.; Scheffler, M.; Helge, H.; Roots, I. Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin. Pharmacol. Ther., 1992, 52(2), 170-80.
94. Doki, K.; Homma, M.; Kuga, K.; Aonuma, K.; Kohda, Y. Effects of CYP2D6 genotypes on age-related change of flecainide metabolism: involvement of CYP1A2-mediated metabolism. Br. J. Clin. Pharmacol., 2009, 68(1), 89-96.
95. Rizzo, N.; Padoin, C.; Palombo, S.; al., E. Omeprazole and lansoprazole are not inducers of cytochrome P4501A2 under conventional therapuetic conditions. Eur. J. Clin. Pharmacol., 1996, 49, 491-5.
96. Kotake, A.N.; Schoeller, D.A.; Lambert, G.H.; Baker, A.L.; Schaffer, D.D.; Josephs, H. The caffeine CO2 breath test: dose response and route of N-demethylation in smokers and nonsmokers. Clin. Pharmacol. Ther., 1982, 32(2), 261-9.
97. Aldridge, A.; Parsons, W.D.; Neims, A. Stimulation of caffeine metabolismin the rat by 3-methylcholanthrene. Life Sci., 1977, 21, 967-974.
98. Goldman, H.D.; Kotake, A.N. The use of 1, 3, 7 4C trimethylcaffeine breath test as an in vivo measure of polycyclic aromatic hydroxylase activity. Pharmacologist, 1979, 21, 206.
99. Wietholtz, H.; Voegelin, M.; Arnaud, M.J.; Bircher, J.; Preisig, R. Assessment of the cytochrome P-448 dependent liver enzyme system by a caffeine breath test. Eur. J. Clin. Pharmacol., 1981, 21(1), 53-9.
100. Lambert, G.H.; Schoeller, D.A.; Humphrey, H.E.; Kotake, A.N.; Lietz, H.; Campbell, M.; Kalow, W.; Spielberg, S.P.; Budd, M. The caffeine breath test and caffeine urinary metabolite ratios in the Michigan cohort exposed to polybrominated biphenyls: a preliminary study. Environ. Health Perp., 1990, 89, 175-81.
101. Lambert, G.H.; Schoeller, D.A.; Kotake, A.N.; Flores, C.; Hay, D. The effect of age, gender, and sexual maturation on the caffeine breath test. Dev. Pharmacol. Therap., 1986. 9(6), 375-88.
102. Callahan, M.M.; Robertson, R.S.; Branfman, A.R.; McComish, M.F.; Yesair, D.W. Comparison of caffeine metabolism in three nonsmoking populations after oral administration of radiolabeled caffeine. Drug Metab. Dispos., 1983, 11(3), 211-7.
103. Park, G.J.-H.; Katelaris, P.H.; Jones, D.B.; Seow, F.; Le Couteur, D.G.; Ngu, M.C. Validity of the 13C-caffeine breath test as a noninvasive, quantitative test of liver function. Hepatology, 2003, 38(5), 1227-36.
104. Meyer-Wyss, B.M.; Hildebrand, P.; Beglinger, C., Breath Tests: diagnostic studies. Stables isotopes in pharmaceutical research, ed. T.R. Browne. Vol. 1. 1997, Amsterdam: Elsevier Science Publishers.
105. Gorodischer, R.; Burtin, P.; Hwang, P.; Levine, M.; Koren, G. Saliva versus blood sampling for therapeutic drug monitoring in children: patient and parental preferences and an economic analysis. Ther. Drug Monit., 1994, 16(5), 437-43.
106. Hold, K.M.; de Boer, D.; Zuidema, J.; Maes, R.A. Saliva as an analytical tool in toxicolog. Int. J. Drug Test, 1996, 1, 1-31.
107. Milne, R.W.; Dawes, C. The relative contributions of different salivary glands to the blood group activity of whole saliva in humans. Vox Sanguinis, 1973, 25(4), 298-307.
108. Van Dam, J.G.; Van Loenen, A.C. De aanwezigheid van geneesmiddelen in speeksel. Pharmaceutisch Weekblad, 1978, 113, 65-74.
109. Vining, R.F.; McGinley, R.A. Transport of steroids from blood to saliva. in The Ninth Tenovus workshop. 1982. Cardiff: Alpha Omega Publishing Limited.
110. Dawes, C. Circadian rhythms in human sliavary flow rate and compostition. J. Physiol., 1972, 220, 529-545.
111. Caddy, B., Saliva as a specimen for drug analysis. Advances in Toxicology, ed. R.C. Baselt. Vol. 1. 1984, Foster: Biomedical Publications.
112. Landon, J.; Mahmod, S. Immunoassays of steroids in saliva. in The ninth Tenovus workshop. 1982. Cadiff: Alpha Omega Publishing Limited.
113. Matin, S.B.; Wan, S.H.; Karam, J.H. Pharmacokinetics of tolbutamide: prediction by concentration in saliva. Clin. Pharmacol. Ther., 1974, 16(6), 1052-8.
114. Feller, K.; le Petit, G. On the distribution of drugs in saliva and blood plasma. Int. J. Clin. Pharm. Ther., 1977, 15(10), 468-9.
115. Mullangi, R.; Agrawal, S.; Srinivas, N.R. Measurement of xenobiotics in saliva: is saliva an attractive alternative matrix? Case studies and analytical perspectives. Biomed. Chromatogr., 2009, 23(1), 3-25.
116. Danhof, M.; Breimer, D.D. Therapeutic drug monitoring in saliva. Clin. Pharmacokinet., 1978, 3(1), 39-57.
117. Drobitch, R.K.; Svensson, C.K. Therapeutic drug monitoring in saliva. An update. Clin. Pharmacokinet., 1992, 23(5), 365-79.
118. Horning, M.G.; Brown, L.; Nowlin, J.; Lertratanangkoon, K.; Kellaway, P.; Zion, T.E. Use of saliva in therapeutic drug monitoring. Clin. Chem., 1977, 23(2 PT. 1), 157-64.
119. Dawes, C.; Macpherson, L.M.D. Effects of 9 different chewinggums and lozenges on salivary flow-rate and p H. Caries Res., 1992, 26, 176-182.
120. Doude van Troostwijk, L.J.A.E.; Koopmans, R.P.; Guchelaar, H.-J. Two novel methods for the determination of CYP1A2 activity using the paraxanthine/caffeine ratio. Fundam. Clin. Pharmacol., 2003, 17(3), 355-62.
121. Tantcheva-Poor, I.; Zaigler, M.; Rietbrock, S.; Fuhr, U. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics, 1999, 9(2), 131-44.
122. Bozikas, V.P.; Papakosta, M.; Niopas, I.; Karavatos, A.; Mirtsou- Fidani, V. Smoking impact on CYP1A2 activity in a group of patients with schizophrenia. Eur. Neuropsychopharm., 2004, 14(1), 39-44.
123. Aklillu, E.; Carrillo, J.A.; Makonnen, E.; Hellman, K.; Pitarque, M.; Bertilsson, L.; Ingelman-Sundberg, M. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol. Pharmacol., 2003, 64(3), 659-69.
124. Simon, T.; Becquemont, L.; Hamon, B.; Nouyrigat, E.; Chodjania, Y.; Poirier, J.M.; Funck-Brentano, C.; Jaillon, P. Variability of cytochrome P450 1A2 activity over time in young and elderly healthy volunteers. Br. J. Clin. Pharmacol., 2001, 52(5), 601-4.
125. Faber, M.S.; Jetter, A.; Fuhr, U. Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin. Pharmacol. Toxicol., 2005, 97(3), 125-34.
126. Daly, J.W.; Fredholm, B.B. Caffeine: An atypical drug of dependence. Drug Alcohol Depend, 1998, 51(1-2), 199-206.
127. Cholerton, S.; Daly, A.K.; Idle, J.R. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol. Sci., 1992, 13(12), 434-9.
128. Kato, M. Intestinal first-pass metabolism of CYP3A4 substrates. Drug Metab. Pharmacok., 2008, 23(2), 87-94.
129. Hetzler, R.K.; Knowlton, R.G.; Somani, S.M.; Brown, D.D.; Perkins, R.M., 3rd. Effect of paraxanthine on FFA mobilization after intravenous caffeine administration in humans. J. Appl. Physiol., 1990, 68(1), 44-7.
130. Lee, T.C.; Charles, B.; Steer, P.; Flenady, V.; Shearman, A. Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity. Clin. Pharmacol. Ther., 1997, 61(6), 628-40.
131. Newton, R.; Broughton, L.J.; Lind, M.J.; Morrison, P.J.; Rogers, H.J.; Bradbrook, I.D. Plasma and salivary pharmacokinetics of caffeine in man. Eur. J. Clin. Pharmacol., 1981, 21(1), 45-52.
132. Nickell, P.V.; Uhde, T.W. Dose-response effects of intravenous caffeine in normal volunteers. Anxiety, 1994, 1(4), 161-8.
133. Nordmark, A.; Lundgren, S.; Cnattingius, S.; Rane, A. Dietary caffeine as a probe agent for assessment of cytochrome P4501A2 activity in random urine samples. Br. J. Clin. Pharmacol., 1999, 47(4), 397-402.
134. Le Marchand, L.; Franke, A.A.; Custer, L.; Wilkens, L.R.; Cooney, R.V. Lifestyle and nutritional correlates of cytochrome CYP1A2 activity: inverse associations with plasma lutein and alphatocopherol. Pharmacogenetics, 1997, 7(1), 11-9.
135. Peterson, S.; Lampe, J.W.; Bammler, T.K.; Gross-Steinmeyer, K.; Eaton, D.L. Apiaceous vegetable constituents inhibit human cytochrome P-450 1A2 (hCYP1A2) activity and hCYP1A2- mediated mutagenicity of aflatoxin B1. Food Chem. Toxicol., 2006, 44(9), 1474-84.
136. Carrillo, J.A.; Benitez, J. CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine. Br. J. Clin. Pharmacol., 1996, 41(6), 605-8.
137. Balogh, A.; Harder, S.; Vollandt, R.; Staib, A.H. Intra-individual variability of caffeine elimination in healthy subjects. Int. J. Clin. Pharmacol. Ther. Toxicol., 1992, 30(10), 383-7.
138. Peterson, S.; Schwarz, Y.; Li, S.S.; Li, L.; King, I.B.; Chen, C.; Eaton, D.L.; Potter, J.D.; Lampe, J.W. CYP1A2, GSTM1, and GSTT1 polymorphisms and diet effects on CYP1A2 activity in a crossover feeding trial. Cancer Epidem. Biomar., 2009, 18(11), 3118-25.
139. Faber, M.S.; Fuhr, U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Pharmacok Drug Disp, 2004. 76(2): p. 178-184.
140. Berthou, F.; Goasduff, T.; Dreano, Y.; Menez, J.F. Caffeine increases its own metabolism through cytochrome P4501A induction in rats. Life Sci., 1995 57(6), 541-9.
141. Caraco, Y.; Zylber-Katz, E.; Granit, L.; Levy, M. Does restriction of caffeine intake affect mixed function oxidase activity and caffeine metabolism? Biopharm. Drug Dispos., 1990, 11(7), 639-43.
142. Masimirembwa, C.M.; Beke, M.; Hasler, J.A.; Tang, B.K.; Kalow, W. Low CYP1A2 activity in rural Shona children of Zimbabwe. Clin. Pharmacol. Ther., 1995, 57(1), 25-31.
143. Marks, V.; Kelly, J.F. Absorption of caffeine from tea, coffee, and coca cola. Lancet, 1973, 1(7807), 827.
144. Bae, S.K.; Park, S.-J.; Shim, E.-J.; Mun, J.-H.; Kim, E.-Y.; Shin, J.- G.; Shon, J.-H. Increased oral bioavailability of itraconazole and its active metabolite, 7-hydroxyitraconazole, when coadministered with a vitamin C beverage in healthy participants. J. Clin. Pharmacol., 2011, 51(3), 444-51.
145. Malhotra, S.; Dixit, R.K.; Garg, S.K. Effect of an acidic beverage (Coca-Cola) on the pharmacokinetics of carbamazepine in healthy volunteers. Meth. Find Exp. Clin., 2002, 24(1), 31-3.
146. McCusker, R.R.; Goldberger, B.A.; Cone, E.J. Caffeine content of energy drinks, carbonated sodas, and other beverages. J. Anal Toxicol., 2006, 30(2), 112-4.
147. Stavric, B.; Klassen, R.; Watkinson, B.; Karpinski, K.; Stapley, R.; Fried, P. Variability in caffeine consumption from coffee and tea: possible significance for epidemiological studies. Food Chem. Toxicol., 1988, 26(2), 111-8.
148. Bateman, D.N. Effects of meal temperature and volume on the emptying of liquid from the human stomach. J. Physiol., 1982, 331, 461-7.
149. Sun, W.M.; Houghton, L.A.; Read, N.W.; Grundy, D.G.; Johnson, A.G. Effect of meal temperature on gastric emptying of liquids in man. Gut, 1988, 29(3), 302-5.
150. Boekema, P.J.; Lo, B.; Samsom, M.; Akkermans, L.M.; Smout, A.J. The effect of coffee on gastric emptying and oro-caecal transit time. Eur. J. Clin. Invest., 2000, 30(2), 129-34.
151. Kamimori, G.H.; Karyekar, C.S.; Otterstetter, R.; Cox, D.S.; Balkin, T.J.; Belenky, G.L.; Eddington, N.D. The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers. Int. J. Pharm., 2002, 234(1-2), 159-67.
152. Kadlubar, F.F.; Talaska, G.; Butler, M.A.; Teitel. C.H.; Massengill J.P.; Lang, N.P. Determination of carcinogenic arylamine Noxidation phenotype in humans by analysis of caffeine urinary metabolites. Prog. Clin. Biol. Res., 1990, 340B, 107-14.